Table 3.
Upgrading related to radiological changes on MRI in MRI‐positive and ‐negative men per definition for csPCa at 1‐year surveillance.
| Definition I | Definition II | Definition III | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow‐up MRI at 1‐year surveillance | No upgrading | Upgrading | No upgrading | Upgrading | No upgrading | Upgrading | |||||||||||
| N (% of total) | Overall, n (%) or n/N | Overall, n (%) or n/N | Biopsy technique, n (% of overall) or n/N | Overall, n (%) or n/N | Overall, n (%) or n/N | Biopsy technique, n/N | Overall, n (%) or n/N | Overall, n (%) or n/N | Biopsy technique, n/N | ||||||||
| All biopsy | TBx + SBx | SBx only | TBx only | All biopsy | TBx + SBx | SBx only | TBx only | All biopsy | TBx + SBx | SBx only | TBx only | ||||||
| Total | PRECISE 4–5 | 17 (15) | 10 (59) | 7 (41) | 1 (14) | 3 (43) | 3 (43) | 14 (82) | 3 (18) | 0/3 | 3/3 | 0/3 | 16 (94) | 1 (6) | 0/1 | 1/1 | 0/1 |
| PRECISE 1–3 | 94 (85) | 66 (70) | 28 (30) | 12 (43) | 12 (43) | 4 (14) | 80 (85) | 14 (15) | 4/14 | 7/14 | 3/14 | 90 (96) | 4 (4) | 1/4 | 2/4 | 1/4 | |
| Positive MRI | PRECISE 4–5 | 17 (27) | 10 (59) | 7 (41) | 1/7 | 3/7 | 3/7 | 14 (82) | 3 (18) | 0/3 | 3/3 | 0/3 | 16 (94) | 1 (6) | 0/1 | 1/1 | 0/1 |
| PRECISE 1–3 | 46 (73) | 23 (50) | 23 (50) | 12 (52) | 7 (30) | 4 (17) | 35 (76) | 11 (24) | 4/11 | 4/11 | 3/11 | 43 (93) | 3 (7) | 1/3 | 1/3 | 1/3 | |
| Negative MRI | PRECISE 4–5 | N/A | |||||||||||||||
| PRECISE 1–3 | 48 (100) | 43 (90) | 5 (10) | x | 5/5 | x | 45 (94) | 3 (6) | x | 3/3 | x | 47 (98) | 1 (2) | x | 1/1 | x | |
| PRECISE 3 | 42 (88) | 38 (90) | 4 (10) | x | 4/4 | x | 40 (95) | 2 (5) | x | 2/2 | x | 41 (98) | 1 (2) | x | 1/1 | x | |
| PRECISE 1–2 | 6 (13) | 5/6 | 1/6 | x | 1/1 | x | 5/6 | 1/6 | x | 1/1 | x | 6/6 | 0/6 | x | 0/0 | x | |
PRECISE, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation; SBx, systematic biopsy; TBx, targeted biopsy.